1-(2-ethylamine)-pyrrolidine | 1824090-46-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 1-(2-ethylamine)-pyrrolidine
• 英文别名: pyrrolidino-ethylamine；1-ethylaminopyrrolidine；1-Pyrrolidinamine, N-ethyl-；N-ethylpyrrolidin-1-amine
• CAS: 1824090-46-1
• 化学式: C₆H₁₄N₂
• 分子量: 114.191
• InChiKey: UQWLYCWPEFZWMO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  8
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(2-ethylamine)-pyrrolidine 、 3-碘苄胺 生成 (2R,3R,4S,5R)-2-[6-(3-Iodo-benzylamino)-2-(2-pyrrolidin-1-yl-ethylamino)-purin-9-yl]-5-(2-methyl-2H-tetrazol-5-yl)-tetrahydro-furan-3,4-diol bis(formate)
  参考文献：
  名称：

  2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives

  摘要：

  根据本发明提供了一种新型化合物，其化学式为I1，其中R1、R2和R3如规范中所述，还提供了制备这些化合物的方法、含有它们的配方以及它们在治疗炎症性疾病中的用途。

  公开号：

  US20020086850A1
• 作为试剂：
  描述：

  2-羟基-3-甲基-5-溴苯甲酸甲酯 在 盐酸 、 氨 作用下， 以 1-(2-ethylamine)-pyrrolidine 为溶剂， 以80%的产率得到N(2'-pyrrolidino-ethyl)-5-bromo-3-methyl-salicylamide hydrochloride
  参考文献：
  名称：

  Amides of pyrrolidinoethylamine which can be used in treatment of coughs

  摘要：

  新的化合物，为吡咯烷基乙胺酰胺，以其自由碱和盐的形式存在，可用作止咳药，包括药物组合物和治疗方法。这些化合物的盐的结构式如下：##STR1## 其中##STR2##是苯乙酸、60-苯基-α-(1至5个碳原子)乙酸、(1至5个碳原子)二苯乙酸、苯甲酸、二苯基-α-氯乙酸、α-较低烷氧基-α，α-二苯乙酸、3-香豆素羧酸、9-蒽羧酸、苯氧基乙酸、苯氧基异丁酸、卤代苯氧基异丁酸或9-氟芴羧酸的酰基基团，R'H代表无机或有机酸。含有这些活性成分的药物可用于治疗咳嗽和呼吸系统疾病等疾病。

  公开号：

  US04122199A1

文献信息

• [EN] ARYLPYRAZOLES AND ARYLISOXAZOLES AND THEIR USE AS PKD MODULATORS<br/>[FR] ARYLPYRAZOLES ET ARYLISOXAZOLES ET LEUR UTILISATION EN TANT QUE MODULATEURS DE LA PROTÉINE KINASE C (PKD)
  申请人：NOVARTIS AG

  公开号：WO2011009484A1

  公开（公告）日：2011-01-27

  The present invention provides novel organic compounds of formula (I) or (Ia): which may be inhibitors of a selective subset of kinases belonging to the AGC or calmodulin kinase family, such as for example PKD-1/2/3, inhibitors of histone deacetylase (HDAC) phosphorylation, or inhibitors of other kinases. The selectivity of which would depend on the structural variation thereof, and for treatment of a disorder or disease mediated by those selected AGC or calmodulin family kinases. These organic compounds can be used to treat various PKD associated states such as heart failure, colorectal cancer, regulation of cell growth, autoimmune disorders, or hyperproliferative skin disorders.

  本发明提供了化学式(I)或(Ia)的新型有机化合物：这些化合物可能是AGC或钙调素激酶家族中的一部分激酶的抑制剂，例如PKD-1/2/3，组蛋白去乙酰化酶（HDAC）磷酸化的抑制剂，或其他激酶的抑制剂。其选择性取决于其结构变化，用于治疗由这些选定的AGC或钙调素家族激酶介导的疾病或疾病。这些有机化合物可用于治疗各种PKD相关状态，如心力衰竭、结直肠癌、细胞生长调节、自身免疫性疾病或过度增生性皮肤疾病。
• GLUCOKINASE ACTIVATORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE INGREDIENT
  申请人：Kim Soon Ha

  公开号：US20100267708A1

  公开（公告）日：2010-10-21

  The present invention relates to new compounds of formula (1) exhibiting excellent activity for glucokinase, and pharmaceutical compositions comprising the same as an active ingredient.

  本发明涉及公式（1）的新化合物，表现出对葡萄糖激酶的优异活性，并且包括该化合物作为活性成分的药物组合物。
• AMINOPYRIMIDINES AS KINASE MODULATORS
  申请人：Gaul David Michael

  公开号：US20060281764A1

  公开（公告）日：2006-12-14

  The invention is directed to aminopyrimidine compounds of Formula I: where R 3 , B, Z, Q, p, q and R 1 are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of FLT3 and/or c-kit and/or TrkB, the use of such compounds to reduce or inhibit kinase activity of FLT3 and/or c-kit and/or TrkB in a cell or a subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to FLT3 and/or c-kit and/or TrkB. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.

  该发明涉及式I的氨基嘧啶化合物：其中R3、B、Z、Q、p、q和R1如本文中所定义，该类化合物的用途为蛋白酪氨酸激酶调节剂，特别是FLT3和/或c-kit和/或TrkB的抑制剂，该类化合物的用途是在细胞或主体中减少或抑制FLT3和/或c-kit和/或TrkB的激酶活性，并且该类化合物的用途是用于预防或治疗主体中的细胞增殖紊乱和/或与FLT3和/或c-kit和/或TrkB相关的紊乱。本发明进一步涉及包括本发明化合物的药物组合物以及用于治疗癌症和其他细胞增殖紊乱等疾病的方法。
• DISUBSTITUTED UREAS AS KINASE INHIBITORS
  申请人：Furet Pascal

  公开号：US20090131437A1

  公开（公告）日：2009-05-21

  The invention relates to compounds of the formula (I), their use as kinase inhibitors, new pharmaceutical formulations comprising said compounds, said compounds for use in the diagnostic or therapeutic treatment of warm-blooded animals, especially humans, their use in the treatment of diseases or for the manufacture of pharmaceutical formulations useful in the treatment of diseases that respond to modulation of kinase activity, methods of treatment comprising administration of said compounds to a warm-blooded animal, especially a human, and processes for the manufacture of said compounds.

  该发明涉及式(I)的化合物，其作为激酶抑制剂的用途，包括所述化合物的新药物配方，所述化合物用于诊断或治疗温血动物，特别是人类，其用于治疗疾病或用于制造对激酶活性调节产生反应的疾病治疗药物配方的用途，包括将所述化合物用于治疗温血动物，特别是人类的治疗方法，以及所述化合物的制造方法。
• [EN] EphA4 INHIBITORS AS NEUROPROTECTIVE AGENTS<br/>[FR] INHIBITEURS D'EPHA4 EN TANT QU'AGENTS NEUROPROTECTEURS
  申请人：UNIV HONG KONG SCIENCE & TECHN

  公开号：WO2015007222A1

  公开（公告）日：2015-01-22

  Provided is the discovery of the role of EphA4 signaling in neurodegenerative disorders involving β-amyloid induced neurotoxicity such as Alzheimer's Disease. New therapeutic methods, therapeutic agents, and kits for treating diseases caused or exacerbated by overactivated EphA4 signaling are provided. Also provided are methods for identifying additional compounds as therapeutic agents useful for treating conditions involving overly active EphA4 signaling.

  提供了EphA4信号在涉及β-淀粉样蛋白诱导的神经毒性等神经退行性疾病中的作用发现，如阿尔茨海默病。提供了用于治疗由过度活化的EphA4信号引起或加重的疾病的新疗法、治疗剂和工具。还提供了用于识别额外化合物作为治疗剂，对治疗涉及过度活跃的EphA4信号的条件有用的方法。